-
Share
08/07/09
22:47
Share
It gives me comfort seeing GSK actively promote Relenza and seek improvements in delivery and production.
Biota should really be pushing the PR bandwagon, nothing else reflects success as well as a rising share price!
My wish list includes a full nasdaq listing, this would increase analyst coverage and remove the need for active promotion to some degree.
It is now "mid-year"... LANI is due now. Let's keep our fingers crossed... hope for a license deal to a large pharma (not DS).
-